Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Other: 2020-2025

Historic Receivables - Other for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $1.7 million.

  • Tarsus Pharmaceuticals' Receivables - Other rose 49.87% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 49.87%. This contributed to the annual value of $1.3 million for FY2024, which is 18.85% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Receivables - Other stood at $1.7 million for Q3 2025, which was down 9.97% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables - Other peaked at $7.2 million during Q1 2021, and registered a low of $139,000 during Q3 2021.
  • Moreover, its 3-year median value for Receivables - Other was $1.3 million (2024), whereas its average is $1.2 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Receivables - Other surged by 13,800.00% in 2021 and then slumped by 95.75% in 2022.
  • Tarsus Pharmaceuticals' Receivables - Other (Quarterly) stood at $200,000 in 2021, then surged by 1,691.00% to $3.6 million in 2022, then tumbled by 69.49% to $1.1 million in 2023, then grew by 18.85% to $1.3 million in 2024, then skyrocketed by 49.87% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.9 million for Q2 2025, and $1.7 million during Q1 2025.